Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

My previous session
Most popular
Delayed Quote. Delayed  - 08/20 10:00:00 pm
38.41 USD   +0.68%
08/13MYLAN : Launches First Generic for Adcirca® Tablets
08/09Perrigo plans to separate prescription pharma business
08/08MYLAN : 8-k/a
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Drug industry on tenterhooks as Maryland price-gouging law nears

share with twitter share with LinkedIn share with facebook
share via e-mail
09/15/2017 | 01:20pm CEST
A pharmacy employee dumps pills into a pill counting machine as she fills a prescription while working at a pharmacy in New York

(Reuters) - As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation's first law designed to punish drugmaker price-gouging.

The state Attorney General's office said it will field complaints and investigate "unconscionable increases" in essential generic medicines when the closely watched law takes effect Oct. 1.

Drugmakers fear the Maryland law will embolden other states and are seeking a court injunction. Both sides made their arguments on Thursday before a U.S. District Court judge in Baltimore, who could decide on an injunction in the coming days.

Anticipating the law will survive the legal challenge, the Attorney General's office said it is working with health economists at Johns Hopkins University to identify price spikes, which are not made public by drugmakers. Patient advocacy groups are urging consumers to report increased costs for their medicines. Maryland Citizens' Health Initiative will add an option to report price gouging to its website.

Pharmaceutical companies have so far dodged stricter federal oversight despite growing outrage over price hikes. Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) raised the price of heart medications Isuprel by about 720 percent and Nitropress by 310 percent, after acquiring them in 2015. Mylan NV (>> Mylan NV) raised the price of its life-saving EpiPen six-fold between 2008 and 2016.

But states, struggling to cover rising healthcare costs, are taking up the fight. At least 176 bills on pharmaceutical pricing and payment have been introduced this year in 36 states, according to the National Conference of State Legislatures.

Maryland's law is the most aggressive legislation to be passed so far, and allows the state to levy fines and order a reversal of price increases.

The Association for Accessible Medicines, a generic industry trade group that filed the lawsuit, argues that the law is unconstitutional because it does not define price-gouging and amounts to intervention by an individual state in interstate commerce.

"The issue of drug pricing is a national issue ... not something that should be handled piecemeal in 50 different ways," said Jeff Francer, general counsel for the trade group which represents companies like Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) and Novartis AG's (>> Novartis) Sandoz unit.

Maryland Attorney General Brian Frosh said that states have a well-defined role to play in policing "unconscionable" business activity against consumers, especially when they have no other recourse. He cited consumer contracts for telephone service, which are non-negotiable.


The measure applies only to older, off-patent drugs. Generic copies of branded products, usually much cheaper than the originals, account for around 89 percent of U.S. prescription volume, but only 26 percent of total drug spending, according to Quintiles IMS Holdings Inc (>> Quintiles IMS Holdings Inc).

But price spikes on some critical treatments have hit consumers hard. The U.S. Government Accountability Office last year found that 315 generic drugs more than doubled in price since 2010.

Maryland's Frosh said the aim is to deter future steep increases. Before the law was passed, drugmakers had suggested setting a minimum increase of 100 percent as a threshold for investigation, but state officials feared that would incentivize price hikes up to that point, according to Frosh’s office.

Several states have passed laws requiring drugmakers to disclose price increases, but the Maryland law is one of a few drawing the most attention from the drug industry.

Nevada has been sued by two industry trade groups after passing in June a law requiring diabetes drugmakers to justify price increases above a certain amount.

Ohio voters next year will decide on a ballot measure requiring drugmakers to offer state groups the same discounts given to the federal Department of Veterans Affairs. A similar measure failed in California last year, but the state's legislature this week approved a drug pricing bill requiring drugmakers to justify price increases over 16 percent in a two-year period. It now goes to the state's governor for a final decision.

"The states have decided to try and deal with this on their own," said David Gibbons an attorney at Hyman, Phelps & McNamara, which specializes in pharmaceutical and biotechnology companies.

(Reporting by Deena Beasley in Los Angeles; Editing by Michele Gershberg and Lisa Shumaker)

By Deena Beasley

Stocks mentioned in the article
ChangeLast1st jan.
MYLAN NV 0.68% 38.41 Delayed Quote.-9.83%
NOVARTIS 0.49% 82.88 Delayed Quote.0.58%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN NV
08/17TODAY’S RESEARCH REPORTS ON STOCKS T : Teva Pharmaceutical and Mylan
08/13MYLAN : Launches First Generic for Adcirca® Tablets
08/09Perrigo plans to separate prescription pharma business
08/08MYLAN : 8-k/a
08/08MYLAN : Earnings Presentation
08/08MYLAN : Q2 2018 Non-GAAP Reconciliations
08/08MYLAN : Updated Mylan Statement on U.S. Supply of EpiPen® (epinephrine injection..
08/08MYLAN : Statement from Mylan's Board of Directors
08/08MYLAN : Reports Second Quarter 2018 Results and Updates 2018 Guidance
08/08MYLAN NV : Mylan N.V. to Host Earnings Call
More news
News from SeekingAlpha
08/20Class action suit against Mylan and Pfizer to proceed 
08/20ANTARES PHARMA : Proven Business Model Set To Move Much Higher 
08/19Adamis Looks Cheap Despite Serious Leadership Concerns 
08/16White House proposing cuts in opioid production 
08/16FDA approves Teva's generic EpiPen; shares +5.7% 
Financials ($)
Sales 2018 11 615 M
EBIT 2018 3 384 M
Net income 2018 922 M
Debt 2018 12 990 M
Yield 2018 -
P/E ratio 2018 13,77
P/E ratio 2019 13,22
EV / Sales 2018 2,81x
EV / Sales 2019 2,47x
Capitalization 19 665 M
Duration : Period :
Mylan NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 46,8 $
Spread / Average Target 23%
EPS Revisions
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Haribabu Bodepudi Chief Operating Officer
Kenneth Scott Parks Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-9.83%19 665
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY24.70%183 667